In accordance with this, we found that the single blockade of PD-L1 or in combination with PD-1 did not have any beneficial effects on activated CD4+CD25+ T cells but, in fact, further increased the expression of alternate ICs, such as TIM-3 and LAG-3 (new emerging therapeutic targets for cancer). The gene discussed is PDCD1; the disease is cancer.